Eris Lifesciences Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Eris Lifesciences Ltd Announces Strategic Partnership with Natco Pharma Ltd for Semaglutide Launch in India".
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts more than Nifty Smallcap 250 and 3.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eris Lifesciences has announced a strategic partnership with Natco Pharma to commercialise Semaglutide, a GLP-1 receptor agonist used for Type 2 diabetes and weight management, in India. Natco has already received CDSCO approval to manufacture generic semaglutide, and the launch is expected in March 2026. Eris will leverage its established diabetes franchise and wide specialist network of endocrinologists and diabetologists, while Natco contributes manufacturing and regulatory capabilities. The partnership targets India's fast-growing metabolic care segment, where diabetes and obesity prevalence is rising rapidly. Eris has positioned this as a long-term value driver for its chronic care business.
Positive for shareholders — gives Eris entry into the high-growth GLP-1 segment (globally a blockbuster drug category) without manufacturing risk, using Natco's existing approval. Likely to be viewed as a value-accretive move that strengthens Eris's diabetes franchise, though commercial uptake and pricing competition will be key things to watch once launched.